Trolle Christian, Rittig Søren, Frøkjær Jørgen, Jørgensen Jens Otto Lunde
Medicinsk Endokrinologisk Afdeling, Aarhus Universitetshospital, Nørrebrogade, Denmark.
Ugeskr Laeger. 2012 Apr 9;174(15):1019-22.
New treatment methods of syndrome of inappropriate antidiuretic hormone secretion (SIADH) has emerged with the oral vasopressin V2-receptor antagonist (VV2RA) tolvaptan, but its therapeutic window remains to be defined. We present the scientific data and describe treatment possibilities of SIADH while raising the questions: "Does the present evidence enable us to identify who to treat with VV2RAs?" and "is VV2RAs justified as first-line treatment?".
随着口服血管加压素V2受体拮抗剂（VV2RA）托伐普坦的出现，抗利尿激素分泌不当综合征（SIADH）有了新的治疗方法，但其治疗窗仍有待确定。我们展示了相关科学数据并描述了SIADH的治疗可能性，同时提出以下问题：“目前的证据能否让我们确定哪些患者适合使用VV2RAs进行治疗？”以及“VV2RAs作为一线治疗是否合理？”
